|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy of oral magnesium therapy in the treatment of chronic constipation in spastic cerebral palsy children:a randomized controlled trial显示文摘Background Constipation is a common problem in children with spastic cerebral palsy(sCP)with a prevalence that reaches 75%.We hypothesized that treating constipation in those children will improve their health and shorten time spent in daily care.Our aim was to evaluate the efficacy and safety of oral magnesium sulfate for treating chronic constipation in children with sCP.Methods A prospective,double-blinded randomized control trial was carried out involving 100 children aged 2-12 years with sCP(level Ⅲ-Ⅴ of the Gross Motor Functional Classification system)and chronic constipation.They were followed up in the Pediatric neurology clinic,Children's hospital,Ain Shams University,May 2017-January 2019.The intervention group(O-Mg)received oral magnesium sulfate 1 mL/kg/day daily for 1 month compared to the placebo.Outcome measures were constipation improvement and decrease in bowel evacuation time after 1 month.Results Initially,weekly bowel movements,constipation scores and stool consistency were comparable in both groups.After 1 month of regular administration of oral magnesium sulfate,the constipation score,stool frequency and consistency improved compared to the placebo group(P<0.001).Effective safe treatment was achieved in 31(68%)and 4(9.5%)patients in the O-Mg and placebo groups,respectively(RR,2.95;95%CI 2.0-4.5)(P<0.001).Painful bowel evacuation attempts spent by mothers decreased from 25(55.6%)of the cases initially to 10(22%)cases after one month in the O-Mg group(P=0.001).In contrast,in the placebo group,the decrease went from 21(50%)cases initially to 18(42.9%)after 1 month and was not significant(P=0.5).Conclusions Oral magnesium sulfate seems effective in alleviating chronic constipation and pain experience in children with sCP.Consequently,saving maternal time spent in daily bowel evacuation attempts. | Sahar M.A.Hassanein Shaymaa M.Deifallah Hend A.Bastawy | 2021 | World Journal of Pediatrics2021，17，1： | 9 |
| 2 | 慢性便秘的治疗药物现状与新进展显示文摘慢性便秘是一种常见的慢性胃肠动力障碍性疾病。大多数人一生中的某个阶段均曾受其影响。本文就近年临床上常用治疗慢性便秘的药物,如泻剂、促动力药、促分泌剂等进行综述,为提高临床治疗慢性便秘的水平,改善治疗方案,实现个体化治疗提供参考。 | 杜鹏强 陈明月 王雪 高天天 司维 | 2016 | 食品与药品2016，18，4： | 6 |
| 3 | 乳果糖联合匹维溴铵治疗慢性功能性便秘的临床研究显示文摘目的 探讨乳果糖联合匹维溴铵治疗慢性功能性便秘的临床效果。方法 选择2010年12月至2013年2月新乐市医院消化内科收治的慢性功能性便秘患者100例,采用随机数字表法平分为乳果糖组和乳果糖联合匹维溴铵组,各50例。乳果糖组使用乳果糖口服液治疗,每次15 m L口服,每日2次,维持治疗28 d;乳果糖联合匹维溴铵组在乳果糖组基础上加用匹维溴铵治疗,每次50 mg口服,每日3次,进餐时服用,维持治疗28 d。比较两组患者的治疗有效率、治疗后不良反应、治疗后的排便次数和粪便性状等情况。结果 乳果糖联合匹维溴铵组治疗的有效率为92.0%,乳果糖组为68.0%,乳果糖联合匹维溴铵组治疗有效率显著高于乳果糖组(χ^2=7.295,P〈0.05);治疗后,乳果糖联合匹维溴铵组平均排便次数显著高于乳果糖组[(7.4±2.1)次/周比(4.7±2.0)次/周,P〈0.05]。乳果糖联合匹维溴铵组治疗后有82.0%的患者粪便性状恢复至Ⅳ~Ⅴ级,高于乳果糖组62.0%,两组治疗后粪便性状分型比较差异有统计学意义(P〈0.05)。乳果糖联合匹维溴铵组2例(4.0%)患者出现腹泻排Ⅶ型水样便,对照组1例(2.0%),两组不良反应发生率比较差异无统计学意义(P〉0.05)。结论 乳果糖联合匹维溴铵治疗慢性功能性便秘临床效果确切,不良反应小。 | 郭丽霞 周雷贵 | 2015 | 医学综述2015，21，13： | 4 |
| 4 | 慢性便秘的研究进展显示文摘慢性便秘是一种常见的慢性胃肠病,是多种疾病的一个症状,临床很常见,涉及到各个学科,与现代饮食结构、人们生活习惯的改变以及各种心理、社会因素是分不开的.便秘病程大于6个月,称之为慢性便秘[1].流行病学显示,便秘与年龄、性别、饮食、职业、情绪等多种因素有关.美国国立卫生机构调查显示全世界便秘的患病率为2%,我国的便秘患病率高达3.7%,通常发达国家的发病率要高于发展中国家[2].本文就慢性便秘的最新研究状况综述如下. | 汤天旭 王贺智 李国文 刘剑 | 2017 | 中国肛肠病杂志2017，37，6： | 3 |
您所在的机构暂未开通此部分的功能，请联系管理员